WO2007034465A2 - Compositions et methodes associees a la modulation d'une reaction a mediation immunitaire - Google Patents

Compositions et methodes associees a la modulation d'une reaction a mediation immunitaire Download PDF

Info

Publication number
WO2007034465A2
WO2007034465A2 PCT/IE2006/000103 IE2006000103W WO2007034465A2 WO 2007034465 A2 WO2007034465 A2 WO 2007034465A2 IE 2006000103 W IE2006000103 W IE 2006000103W WO 2007034465 A2 WO2007034465 A2 WO 2007034465A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
fragment
sigirr
amino acid
peptide
Prior art date
Application number
PCT/IE2006/000103
Other languages
English (en)
Other versions
WO2007034465A3 (fr
Inventor
Kingston Mills
Marina Lynch
Ceire Costelloe
Original Assignee
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin filed Critical The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin
Publication of WO2007034465A2 publication Critical patent/WO2007034465A2/fr
Publication of WO2007034465A3 publication Critical patent/WO2007034465A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • compositions and methods relating to the modulation of an immune-mediated response are provided.
  • the present invention relates to novel methods for modulating an immune- mediated condition, in particular a neurodegenerative disease or inflammatory condition of the brain.
  • the present invention further extends to the use of the cytokine IL-1 F5 and modulation of the SIGIRR receptor in the induction of an anti-inflammatory immune response.
  • cytokines are secreted proteins now known to be expressed by both neurons and glia. Cytokines are active during neural development as well as in the adult nervous system during both normal function and pathological conditions. Different cytokines can exert similar effects on a single cell type - a phenomenon that allows one factor to compensate for another. Additionally most cytokines induce multiple effects in multiple cell types - making it difficult to determine the role of specific cytokines in the regulation of normal physiology.
  • cytokine binding results in the activation of downstream effectors and activation of protein kinases which phosphorylate protein substrates.
  • tyrosine kinases as the signal transducers, either directly or indirectly linked to the intracellular domain of the receptor.
  • the second pathway involves activation of phospholipases that produce small mediators that activate serine-threonine kinases.
  • Cytokines have been divided into "proinflammatory” and "anti-inflammatory” depending on their effects.
  • pro-inflammatory cytokines promote inflammation and anti-inflammatory cytokines suppress the activity of pro-inflammatory cytokines; they suppress genes for pro-inflammatory cytokines such as IL- 1 and interferon ⁇ (IFN gamma). While IFN-gamma possesses anti-viral activity its ability to augment pro-inflammatory cytokine activity and induce nitric oxide have lead to its classification as a pro-inflammatory cytokine.
  • the most thoroughly investigated of the proinflammatory cytokines are IL- 1 and tumour necrosis factor-alpha (TNF- ⁇ ) while the most studied of the anti-inflammatory cytokines are IL-4 and IL-10.
  • the hippocampal formation located on the medial aspect of each hemisphere beneath the cortical structures, comprises the dentate gyrus, the hippocampus proper and the subiculum, and is part of the limbic system. All 3 are composed of temporal lobe allocortex, tucked into an S- shaped scroll along the floor of the lateral ventricle.
  • the largest afferent connection of the hippocampal formation is the perforant path, which projects from layers Il and III of the entorhinal cortex in the temporal lobe.
  • the granule cells give rise to axons that form the mossy fibre pathway, which synapses with the pyramidal cells in area CA3.
  • the pyramidal cells of area CA3 project to the pyramidal cells in CA1 by means of the Schaffer collateral pathway. This is known as the trisynaptic circuit.
  • the hippocampus plays a central role in the storage of memory. Studies involving lesions of the medial temporal lobe of monkeys demonstrated that these animals exhibited severe memory impairment. More recently, evidence for a role for the hippocampus in memory was demonstrated using magnetic resonance imaging and positron emission topography. These techniques assessed blood flow and oxygen consumption in the hippocampus and identified that these parameters fluctuated during learning tasks.
  • NMDA receptor-associated channels generate the late phase of the EPSP and have a higher conductance being permeable to both sodium and potassium but particularly to calcium. Functioning of NMDA receptors depends on glyceine being present in the extracellular fluid in sufficient quantities. The NMDA receptor-associated differs further in that its channel is dual regulated being not only ligand-gated but also voltage-gated. The presence of extracellular magnesium in the pore of the channel means that membrane depolarization must occur in order to allow ion influx through the channel. Membrane depolarization causes electrostatic repulsion of magnesium from its binding site in NMDA receptor-associated channel. Following production of a single action potential, the late phase of EPSP is usually quite short, as magnesium returns to the pore.
  • the Classical IL-1 family - IL-1 ⁇ and IL-1 B lnterleukin 1 is a cytokine that is produced by, and acts on, many different cell types.
  • IL-1 has the ability to upregulate the expression of many genes important in the initiation and regulation of inflammatory conditions. As such IL-1 is critical in the management of the host immune defence.
  • the potency of this cytokine means that any imbalance in IL-1 levels can rapidly lead to the development of many diseases, including rheumatoid arthritis, Alzheimer's disease and Parkinson's disease.
  • the classical members of the IL-1 family consist of IL-1 ⁇ (IL-1 alpha), IL-1 ⁇ (IL- 1 beta), IL-1 receptor antagonist (IL-1 ra) and IL-18.
  • IL-1 ⁇ and IL-1 ⁇ were first isolated in the 1980s. Both IL-1 ⁇ and IL-1 ⁇ have similar properties in that they can activate the same signals and they both bind to the type 1 IL-1 receptor (IL-1 R1 ). However differences in receptor affinities, cellular localization and sites of regulation and expression allow for a divergence of IL-1 ⁇ and IL-1 ⁇ functions in vivo. Studies on knock out mice have shown that IL-1 ⁇ but not IL-1 ⁇ is required for T cell dependent antibody production and IL-1 ⁇ , but not IL-1 ⁇ , is required for fever development. Both IL-1 ⁇ and IL-1 ⁇ are synthesized as precursor models of 31 kDa.
  • Pro- IL-1 ⁇ is biologically active but is retained within the cytoplasm, with little release in the circulation. In comparison IL-1 ⁇ is readily and rapidly exported from the cell. The method of release is thought to involve the packaging of IL-1 ⁇ into vesicles and subsequent ATP-driven exocytosis. Pro IL-1 ⁇ is cleaved by caspase-1 to form mature, biologically active IL-1 ⁇ .
  • IL-1 ⁇ is constitutively expressed at low levels in healthy adult brain by a variety of cell types. In response to local brain injury or insult, IL-1 is over- expressed by the CNS macrophage equivalent cell, the microglia. Microglia are cells that exist in resting and active states and are activated in response to injury. They are thought to be one of the principal producers of IL-1 ⁇ . IL-1 ⁇ overexpression by microglia is also seen in response to acute head trauma, a recognized risk factor for the later development of Alzheimer's disease.
  • IL-1 ⁇ has also been shown to be involved in the inflammatory pathology in multiple sclerosis (MS) and IL-1 receptor antagonist (IL-1 ra) can ameliorate the symptoms of experimental autoimmune encephalitis (EAE), a murine model for MS.
  • MS multiple sclerosis
  • IL-1 receptor antagonist IL-1 ra
  • IL-1 delta A biological role for IL-1 F5 (IL-1 delta) has not yet been identified. IL-1 F5 expression has been observed in a number of tissue types, including the brain, and also in keratinocytes, monocytes and dendritic cells. Expression of IL-1 F5 can be upregulated following stimulation with LPS and a combination of IL-1 beta and TNF alpha.
  • IL-1 F5 neither mimics nor antagonizes actions of IL-1 such as induction of IL-6.
  • SIGIRR single immunoglobulin related receptor
  • SIGIRR-deficient dendritic cells showed increased cytokine production in response to TLR agonists (lipopolysaccharide, CpG oligodeoxynucleotides).
  • SIGIRR-deficient mice had normal susceptibility to systemic lipopolysaccharide toxicity and to intra-peritoneal (i.p). or sub- cutaneous (s.c), inflammation.
  • SIGIRR-deficient mice were more susceptible to intestinal inflammation.
  • inflammation in response to LPS is enhanced in SIGIRR deficient mice.
  • the mechanism by which SIGIRR negatively modulates the immune response remains unclear.
  • US Patent Application No 2005/0058625 discloses a method of treating an inflammatory or autoimmune disease through the administration of the IL-1 delta polypeptide.
  • IL-1 delta mediates an anti-inflammatory response based on observed sequence homology between the IL-1 delta amino acid sequence and the amino acid sequence of IL-1 ra.
  • IL-1 delta has the same function as IL-1 ra and accordingly acts as an antagonist of IL-1 family members by means of antagonising the other members of the IL-1 family by competitively blocking IL-1 from binding to its receptor which mediate an inflammatory immune response.
  • IL-1 F5 (IL-1 delta) mediates an anti-inflammatory effect, not by being an antagonist of IL-1 activity, but rather through binding to the IL-1 superfamily receptor SIGIRR (single immunoglobulin related receptor). IL-1 F5 acts as an agonist to this receptor. Binding of SIGIRR by IL-1 R results in the downstream production of the anti-inflammatory cytokine IL-4 which serves to modulate an anti-inflammatory response.
  • SIGIRR single immunoglobulin related receptor
  • IL-1 F5 mediates an upregulation of PPARgamma this modulation of activity also resulting in the induction of an anti-inflammatory response.
  • the nucleotide sequence of the human IL-1 F5 protein (also known as IL-1 delta) that encodes amino acid SEQ ID NO:2 is provided as SEQ ID NO:1.
  • IL-1 F5 protein also known as IL-1 delta
  • SEQ ID NO:2 The amino sequence of the human IL-1 F5 protein (also known as IL-1 delta) has been previously defined and this is described herein as SEQ ID NO:2 as follows:
  • the nucleotide sequence of the murine IL-1 F5 protein (also known as IL-1 delta) that encodes amino acid SEQ ID NO:4 is provided as SEQ ID NO:3.
  • the amino sequence of the murine IL-1 F5 protein (also known as IL-I delta) has been previously defined and this is described herein as SEQ ID NO:4 as follows:
  • a method of suppressing a pro-inflammatory immune response comprising the step of administering an effective amount of a polynucleotide or a fragment thereof which encodes a protein having SEQ ID NO:2 or SEQ ID NO:4 or a fragment thereof to a individual in need of such treatment.
  • the individual is a mammal.
  • the mammal is a human.
  • the patient is preferably administered IL-1 F5 having the amino acid as defined in SEQ ID NO:2 or SEQ ID NO:4 or a fragment thereof.
  • a second aspect of the present invention provides the use of a polynucleotide or a fragment thereof which encodes a protein having SEQ ID NO:2 or SEQ ID NO:4 or a fragment thereof for the administration to an individual for the suppression of an immune response, said immune response being characterised in that it is mediated through the activation of SIGIRR (single immunoglobulin related receptor).
  • SIGIRR single immunoglobulin related receptor
  • the individual is a mammal.
  • the mammal is a human.
  • the patient is preferably administered IL-1 F5 having the amino acid as defined in SEQ ID N0:2 or a fragment thereof.
  • a third aspect of the present invention provides the use of a polynucleotide or a fragment thereof which encodes a protein having SEQ ID NO:2 or
  • SEQ ID NO:4 in the preparation of a medicament for the downregulation of an immune response.
  • a yet further aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a polynucleotide or a fragment thereof which encodes a protein having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 along with a pharmaceutically acceptable diluent, excipient or carrier.
  • a method for the prophylaxis and/or treatment of an immune-mediated disorder comprising the step of administering a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an analogue, derivative, fragment, variant or peptidomimetic thereof to an individual in need of such treatment.
  • the individual is a mammal.
  • the mammal is a human.
  • the patient is preferably administered IL-1 F5 having the amino acid as defined in SEQ ID NO:2 or a fragment thereof.
  • the inventors predict that the administration of the peptide having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 causes suppression of the pro-inflammatory immune response by binding to and activating the receptor SIGIRR, which in turn mediates downstream signalling which causes an upregulation in the production of the anti-inflammatory cytokine IL-4.
  • IL-1 F5 therefore exerts an anti-inflammatory function by binding to SIGIRR.
  • IL-1 F5 peptide administration results in a decrease in the expression of the pro-inflammatory cytokine IL-1 and in particular IL-1 beta. This effect is seen in the IL-1 producing cells which are present in the brain, central nervous system (CNS) and other neuronal cells.
  • CNS central nervous system
  • the invention extends to amino acid sequences which are at least 80% homologous with the sequence of SEQ ID NO:2 or SEQ ID NO:4. In further embodiments such sequences may be at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% homologous with the amino acid sequence of SEQ ID NO:2.
  • a further aspect of the present invention provides for the use of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an analogue, derivative, fragment, variant or peptidomimetic thereof for the prophylaxis and/or treatment of an immune-mediated disorder.
  • the invention extends to amino acid sequences which are at least 80% homologous with the sequence of SEQ ID NO:2 or SEQ ID NO:4. In further embodiments such sequences may be at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% homologous with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
  • the antiinflammatory properties of IL-1 F5 are exerted in the brain, CNS or other neuronal tissue, by virtue of the binding of SIGIRR by IL-1 F5 and the resultant expression of the anti-inflammatory cytokine IL-4 which serves to modulate immune responses.
  • Such neuronal specific activity of IL-1 F5 confers benefits in that it may be administered to a patient in need of therapy in order to selectively inhibit inflammation in the brain, while not affecting (through immune modulation or downregulation) beneficial immune responses in the periphery.
  • a yet further aspect of the present invention provides the use of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an analogue, derivative, fragment, variant or peptidomimetic thereof in the preparation of a medicament for the suppression of an immune response, said immune response being characterised in that it is mediated through the activation of SIGIRR.
  • the immune response is suppressed in a mammal. In a further embodiment the immune response is suppressed in a human.
  • the individual is a human, preferably the peptide which is used comprises the amino acid as defined in SEQ ID NO:2 or a fragment thereof.
  • the invention extends to amino acid sequences which are at least 80% homologous with the sequence of SEQ ID NO:2 or SEQ ID NO:4. In further embodiments such sequences may be at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% homologous with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
  • the present invention therefore has particular utility in the prevention and/or treatment of neurodegenerative and/or inflammatory conditions and diseases in and of the brain, CNS and neuronal tissue. Accordingly, in a further aspect of the present invention, there is provided a method for the treatment and/or prophylaxis of a neurodegenerative disease or inflammatory condition of the brain, the method comprising the step of administering a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:2 or an analogue, derivative, fragment, variant or peptidomimetic thereof to an individual in need of therapy.
  • the individual is a mammal.
  • the mammal is a human.
  • the patient is preferably administered IL-1 F5 having the amino acid as defined in SEQ ID NO:2 or a fragment thereof.
  • the neurodegenerative disease or condition is selected from the group consisting of: Alzheimer's disease (AD), mild cognitive impairment (MCI), multiple sclerosis (MS), Parkinson's disease, Amyotrophic lateral sclerosis (ALS), Huntington's disease, prion diseases such as CJD, AIDS- related dementia, encephalitis, stroke and head trauma.
  • AD Alzheimer's disease
  • MCI mild cognitive impairment
  • MS multiple sclerosis
  • ALS Amyotrophic lateral sclerosis
  • Huntington's disease prion diseases such as CJD, AIDS- related dementia, encephalitis, stroke and head trauma.
  • the neurodegenerative condition may also include acute inflammation conditions of the brain which result following bacterial and viral infections.
  • a further aspect of the present invention provides for the use of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof for the prophylaxis and/or treatment of a neurodegenerative disease.
  • the neurodegenerative disease is treated in a mammal. In a further embodiment the neurodegenerative disease is treated in a human. Where the individual is a human, preferably the peptide which is used comprises the amino acid as defined in SEQ ID N0:2 or a fragment thereof.
  • the invention extends to amino acid sequences which are at least 85% homologous with the sequence of SEQ ID NO:2 or SEQ ID NO:4. In further embodiments such sequences may be at least 90%, 95%, 96%, 97%, 98%, 99% or 99.5% homologous with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
  • a yet further aspect of the present invention provides the use of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof in the preparation of a medicament for the suppression of a neurodegenerative disease.
  • the neurodegenerative disease may be Alzheimer's disease.
  • Alzheimer's disease exhibits a sustained, chronic over-expression of IL-1 , with IL-1 over-expression being implicated in both the initiation and progression of the characteristic neuropathological changes, observed with Alzheimer's disease progression.
  • the invention extends to a method for the treatment and/or prophylaxis of Alzheimer's disease, the method comprising the steps of: - administering a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:2, or SEQ ID NO:4 or a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof to an individual in need of such treatment.
  • the individual is a mammal.
  • the mammal is a human.
  • the peptide which is administered comprises a peptide having the amino acid sequence of SEQ ID NO:2 or a fragment thereof or a sequence with at least 80% homology thereto.
  • a further aspect of the invention extends to the use of an agent comprising a peptide comprising the amino acid sequence of SEQ ID NO:2, or SEQ ID NO:4 a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof in the treatment of Alzheimer's disease.
  • a further still aspect relates to the use of a peptide comprising the amino acid sequence of SEQ ID NO:2, or SEQ ID NO:4 a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof in the preparation of a medicament for the treatment of Alzheimer's disease.
  • a yet further aspect of the present invention provides a method of treating Alzheimer's disease through direct administration of a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof to the brain, neuronal tissue or the CNS of an individual in need of such treatment.
  • the individual is a mammal.
  • the mammal is a human.
  • the patient is preferably administered a peptide having the amino acid sequence of SEQ ID NO:2 or a fragment thereof or a sequence with at least 80% homology thereto.
  • the IL-1 F5 polypeptide or fragment thereof may delivered to the brain by means of a intracerebroventricular injection (icv / ICV) or through delivery into the CNS using minipumps.
  • icv / ICV intracerebroventricular injection
  • minipumps minipumps
  • a viral vector may be used to target delivery of the IL-1 F5 to the brain or neural tissue.
  • a vector will include a construct which contains a gene encoding for IL-1 F5 or a fragment, derivative, mimetic or analogue thereof.
  • the construct may further contain a promoter which is provided adjacent to the gene and which controls expression of the gene.
  • Viral vectors which may be suitable for such delivery and targeting may be; (i) nonreplicative herpes simplex type 1 viruses (Poliani et al. Hum Gene Ther. 2001 May 20; 12(8):905-20.); (ii) Semliki Forest virus, (Jerusalmi et al. MoI. Ther. 2003 Dec;8(6):886-94.) and (iii) adenovirus, (for example see Braciack et al. J. Immunol. 2003 Jan 15;170(2):765-74.).
  • naked plasmid DNA encoding for IL-1 F5 or fragments, derivative, mimetics or analogues thereof may be directly administered.
  • a further still aspect relates to the use of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereofin the preparation of a medicament for the treatment of Alzheimer's wherein the medicament is administered directly to the brain, neuronal tissue or the CNS of an individual in need of such treatment.
  • the individual is a mammal.
  • the mammal is a human.
  • the patient is preferably administered a peptide having the amino acid sequence of SEQ ID NO:2 or a fragment thereof or a sequence with at least 80% homology thereto.
  • the present invention extends to a method of treating an individual afflicted with Multiple Sclerosis, comprising administering to the individual a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof.
  • a further aspect of the invention extends to the use of an agent comprising a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof in the treatment of Multiple Sclerosis.
  • a further still aspect relates to the use of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof in the preparation of a medicament for the treatment of Multiple Sclerosis.
  • a yet further aspect of the present invention provides a method of treating Multiple Sclerosis through direct administration of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof to the brain or CNS.
  • a further still aspect relates to the use of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof in the preparation of a medicament for the treatment of Multiple Sclerosis wherein the medicament is administered directly to the brain, neuronal tissue or the CNS.
  • a viral vector may be used to target delivery of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof to the brain, neuronal tissue or the CNS.
  • the IL-1 F5 polypeptide or fragment thereof may delivered to the brain by means of a intracerebroventricular injection (icv / ICV), through delivery by a minipump, by using a viral vector targeted to the brain or neural tissue, or by directly administering naked plasmid DNA encoding for IL-1 F5 or fragments, derivative, mimetics or analogues thereof.
  • icv / ICV intracerebroventricular injection
  • minipump a viral vector targeted to the brain or neural tissue
  • naked plasmid DNA encoding for IL-1 F5 or fragments, derivative, mimetics or analogues thereof.
  • a further neural specific indication against which the present invention has utility is cognitive dysfunction.
  • LTP long term potentiation
  • a method for the prophylaxis and/or treatment of cognitive dysfunction comprising the step of administering a therapeutically effective amount of an agent comprising a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof to an individual in need of such therapy.
  • the individual is a mammal.
  • the mammal is a human.
  • the patient is preferably administered a peptide having the amino acid sequence of SEQ ID NO:2 or a fragment thereof or a sequence with at least 80% homology thereto.
  • a further aspect of the invention extends to the use of an agent comprising a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof in the treatment of cognitive dysfunction.
  • a further still aspect relates to the use of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof in the preparation of a medicament for the treatment of cognitive dysfunction.
  • the administration of the a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof results in the up-regulation of anti-inflammatory cytokines, for example IL-4 and the down-regulation of pro-inflammatory cytokines such as IL-I .
  • this upregulation will be in the hippocampus, most preferably this upregulation of the antiinflammatory cytokine profile will be present in the microglial cells.
  • IL-1 F5 be administered to the brain or directly to another area of the central nervous system (CNS).
  • the anti-inflammatory cytokines which are upregulated are IL-4 and IL-10.
  • the pro-inflammatory cytokines which are down-regulated are typically IL-1 beta, and TNF-alpha.
  • the modulation of proinflammatory and anti-inflammatory cytokine levels is in the hippocampus, most preferably this modulation of the cytokine profile will be seen in the microglial cells.
  • the fragment, derivative, analogue or mimetic of the IL-1 F5 polypeptide confers IL-1 F5 activity, that is that the peptide or peptide fragment can maintain long term potentiation, up-regulate the production of anti-inflammatory cytokines and down-regulate proinflammatory cytokines.
  • the IL-1 F5 polypeptide or fragment thereof may be administered directly to the brain or other suitable site of the central nervous system (CNS) in order to deliver the IL-1 F5 polypeptide or fragment thereof to the neural tissue.
  • CNS central nervous system
  • the compositions will be administered in such a way that they are directed to the hippocampus, and in particular can be directed to the microglial cells.
  • a yet further aspect of the present invention provides a method of treating cognitive dysfunction through direct administration of a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof to the brain, neuronal tissue or the CNS.
  • a further still aspect relates to the use of IL-1 F5 a fragment or derivative thereof in the preparation of a medicament for the treatment of cognitive dysfunction wherein the medicament is administered directly to the brain or CNS.
  • the IL-1 F5 polypeptide or fragment thereof may delivered to the brain by means of a intracerebroventricular injection (icv / ICV), through delivery by a minipump, by using a viral vector targeted to the brain or neural tissue, or by directly administering naked plasmid DNA encoding for IL-1 F5 or fragments, derivative, mimetics or analogues thereof.
  • icv / ICV intracerebroventricular injection
  • minipump a viral vector targeted to the brain or neural tissue
  • naked plasmid DNA encoding for IL-1 F5 or fragments, derivative, mimetics or analogues thereof.
  • IL-1 F5 binds to the IL-1 superfamily orphan receptor SIGIRR (single Ig IL-1 R-related molecule). The identification of this binding association provides a further point at which the immune response may be modulated. The binding of IL-1 F5 to SIGIRR activates a signalling pathway which results in the upregulation of IL-4 production.
  • SIGIRR single Ig IL-1 R-related molecule
  • a further aspect of the present invention provides a method for modulating the activity of the SIGIRR receptor through selectively binding it with a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof.
  • Binding of SIGIRR with a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof serves to modulate the immune response through the downstream induction of an anti-inflammatory response, while competitive binding or functional blocking of the SIGIRR binding by a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof results in the stimulation of an inflammatory response.
  • peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof, further molecules may be employed to selectively influence the activity of the SIGIRR receptor, most specifically by influencing whether the receptor is in a bound or unbound state, the result of which will be an associated downstream modulation of the immune response.
  • a yet further aspect of the present invention provides a method for identification of modulator(s) of the binding of IL-1 F5 and the SIGlRR receptor, said method comprising the steps of:
  • the IL-1 F5 is mammalian IL-1 F5. In one embodiment, the IL-1 F5 is human IL-1 F5 or a fragment thereof, with human IL-1 F5 being defined herein as comprising the amino acid sequence of SEQ ID NO:2.
  • the downstream activation of SIGIRR may be monitored by quantifying the upregulation of specific cytokines known the associated with an antiinflammatory response, such as the cytokine IL-4.
  • the activation of SIGIRR can be monitored by quantifying differences in PPAR activation, and in particular PPARgamma activation, which may result from downstream activation of SIGIRR.
  • II- 1 F5 and fragments thereof mediate an anti-inflammatory response, not by 11-1 F5 acting as an antagonist to IL-1 beta, but due to IL-1 F5 acting as an agonist to the SIGIRR receptor, wherein binding of IL-I F5 to SIGIRR results in activation of the receptor and downstream signalling. This signalling results in the activation of IL-4.
  • the inventors have recognised the utility of providing compounds which antagonise SIGIRR, with IL-1 F5 having particular utility in this regard.
  • a method of agonizing the SIGIRR receptor in a patient comprising the step of:
  • a medicament comprising a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof, in an amount effective to bind the SIGIRR receptor as an agonist.
  • the patient is a mammal. In a further embodiment, the patient is a human. Where the patient is a human, the patient is preferably administered IL-1 F5 having the amino acid as defined in SEQ ID NO:2 or a fragment thereof.
  • the method can be used for the suppression of an aberrant immune response.
  • the immune response may be causative of a neurodegenerative disease, for example Alzheimer's disease, multiple sclerosis or mild congnitive impairment, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, prion diseases, encephalitis and head trauma.
  • a neurodegenerative disease for example Alzheimer's disease, multiple sclerosis or mild congnitive impairment, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, prion diseases, encephalitis and head trauma.
  • a peptide comprising the amino acid sequence of SEQ ID NO:2, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof as an agonist in the treatment of a neurodegenerative disease.
  • the peptide comprising the amino acid sequence of SEQ ID NO:2, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof is an agonist to SIGIRR.
  • a peptide comprising the amino acid sequence of SEQ ID NO:2, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof as an agonist of SIGIRR in the preparation of a medicament for the treatment of neurodegenerative disesase.
  • PPAR activation and in particular PPARgamma activation is effected following binding of SIGIRR by IL-1 F5 or a fragment therof.
  • a yet further aspect of the present invention provides for the use of PPARgamme in the modulation of an immune response.
  • the immune response is an anti-inflammatory response mediated by IL-1 F5.
  • the modulator(s) identified according to the above assay method may be a peptide or non-peptide molecule such as a chemical entity or pharmaceutical substance. Where the modulator is a peptide it may be an antibody, or an antibody fragment. Further, where the modulator is an antibody, preferably it is a monoclonal antibody.
  • Novel compounds identified using the assays of the invention form a further independent aspect of the invention.
  • Such compounds or modulators may be provided in pharmaceutical compositions.
  • Such pharmaceutical compositions may be used in the treatment of conditions as hereinbefore described.
  • the assay of the present invention and compounds of biological significance to the SIGIRR signalling pathway which are realised by means of the use of the assays of the invention may have specific utility in the treatment in a number of medical conditions, particularly neurodegenerative diseases, auto-immune conditions or immune mediated conditions.
  • an assay method for the detection of a binding ligand which casuses activation of SIGIRR comprising the steps of:
  • the isotype of PPAR is PPARgamma.
  • the level of activation of SIGIRR can be compared to a control sample, such as the same type of cells which are not exposed to the ligand.
  • the test sample can be controlled to a known, pre-determined reference value.
  • a yet further aspect of the invention provides a kit for the determination of the activation status of the SIGIRR receptor, the kit comprising a reference sample, means for determining the activation status of SIGIRR and instructions for the performance of any of the assays of the invention using the methods described in said aspects.
  • PPARgamma has been shown to have a role in IL-1 F5 inhibition of LPS induced IL-1 expression in glial cells.
  • the use of a PPARgamma antagonist abolishes the IL-1 F5 inhibition of LPS induced IL-1 expression indicating that PPARgamma has a role in IL-1 F5 mediated activation of an anti-inflammatory response, and in particular the suppression of an IL-1 beta mediated pro-inflammatory response.
  • PPARs Peroxisome proliferators activated receptors
  • PPARs are nuclear proteins that modulate gene expression. PPARs act as ligand activated transcription factors that increase transcription of target genes by binding a specific nucleotide sequence in the gene's promoter.
  • IL-1 F5 increases PPARgamma expression in mixed glial cells.
  • PPARgamma (475/505 amino acids is located on chromosome 3p25.1 ).
  • IL-1 F5 PPARgamma activation is necessary for IL- 1 F5 induced inhibition of IL-1 beta.
  • a further still aspect of the present invention provides a method for the prophylaxis and/or treatment of an immune-mediated disorder comprising the step of activating PPAR.
  • the PPAR isotype which is activated is PPARgamma. This activation of PPARgamma modulates the increased expression of IL-
  • a further still aspect of the present invention provides a method of treating an immune-mediated condition in a subject comprising administering to said subject a therapeutically effective amount of a molecule which induces activation and expression of PPARgamma.
  • the individual is a mammal. In a further embodiment the mammal is a human.
  • a yet further aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a peptide comprising the amino acid sequence of SEQ ID NO:2, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof.
  • a yet further aspect of the present invention provides an immunomodulator comprising a peptide comprising the amino acid sequence of SEQ ID NO:2, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof.
  • a yet further aspect of the present invention provides a vaccine composition comprising a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof.
  • a yet further aspect of the present invention provides an antibody or binding fragment with specificity to a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a sequence which is at least 80% homologous thereto, or an analogue, derivative, fragment, variant or peptidomimetic thereof.
  • a yet further aspect of the present invention provides an antibody or binding fragment with specificity to SIGIRR or a derivative or mutant or fragment or variant or peptide thereof.
  • a still further aspect of the present invention provides an antibody or binding fragment with specificity to PPARgamma or a derivative or mutant or fragment or variant or peptide thereof.
  • an "assay system” encompasses all the components required for performing and analysing results of an assay that detects and/or measures a particular event or events.
  • screening assays are available to detect the activation status of PPAR, these will be known to the person skilled in the art. It is preferred, though not essential that the screening assays employed in the present invention are high throughput or ultra high throughput and thus provide an automated, cost-effective means of screening.
  • the present invention extends to peptides which are derivates or homologues of IL-1 F5, such peptides may have a sequence which has at least about 30%, or 40%, or 50%, or 60%, or 70%, or 75%, or 80%, or 85%, or 90%, 95%, 98% or 99% homology to the amino acid sequence of IL-1 F5 as defined in SEQ ID NO:2 or SEQ ID NO:4.
  • a peptide derivative of the IL-1 F5 peptide of the invention may include a number of amino acid alterations, for example 1 , 2, 3, 4, 5 or greater than 5 amino acid alterations.
  • the peptide may consist of a truncated version of IL-1 F5 which has been truncated by 1 , 2, 3, 4 or 5 amino acids.
  • the percentage identity of two amino acid sequences or of two nucleic acid sequences may be determined by aligning the sequences for optimal comparison purposes (e.g. gaps can be introduced in the first sequence for best alignment with the sequence) and comparing the amino acid residues or nucleotides at corresponding positions.
  • the "best alignment” is an alignment of two sequences which results in the highest percent identity.
  • the determination of percent identity between two sequences can be accomplished using a mathematical algorithm known to those skilled in the art.
  • the NBLAST and XBLAST programs are examples of computer programs which perform such algorithms.
  • BLAST nucleotide searches can be performed with the NBLAST program to obtain nucleotide sequences homologous to nucleic acid molecules of the invention.
  • BLAST protein searches can be performed with the XBLAST program to obtain amino acid sequences homologous to protein molecules of the invention.
  • Gapped BLAST can be utilised.
  • PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules (Idem.).
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • XBLAST and NBLAST See URL http://www.ncbi.nlm.nih.gov.
  • a derivative of a peptide for which the specific sequence is disclosed herein may be in certain embodiments the same length or shorter than the specific peptide.
  • the peptide sequence or a variant thereof may include a larger peptide.
  • homology at the amino acid level is generally in terms of amino acid similarity or identity. Similarity allows for 'conservative variation', such as substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as lysine, glutamic acid for aspartic acid, or glutamine for asparagine.
  • Analogues of, and for use in, the invention as defined herein means a peptide modified by varying the amino acid sequence e.g. by manipulation of the nucleic acid encoding the protein or by altering the protein itself. Such derivatives of the amino acid sequence may involve insertion, addition, deletion and/or substitution of one or more amino acids.
  • Mimetics of IL-1 F5 In addition to fragments or derivatives of IL-1 F5, non-peptide mimetics of the IL-1 F5 polypeptide can be used in the performance of the present invention. Such mimetics may be prepared, either wholly or partly, by chemical synthesis. Generation of the peptides in this way can be performed by methods which are well known to the person skilled in the art.
  • treatment is used herein to refer to any regime that can benefit a human or non-human animal.
  • the treatment may be in respect of an existing condition or may be prophylactic (preventative treatment). Treatment may include curative, alleviation or prophylactic effects.
  • therapeutic and “prophylactic” treatment is to be considered in its broadest context.
  • the term “therapeutic” does not necessarily imply that a subject is treated until total recovery.
  • prophylactic does not necessarily mean that the subject will not eventually contract a disease condition.
  • therapeutic and prophylactic treatment includes amelioration of the symptoms of a particular condition or preventing or otherwise reducing the risk of developing a particular condition.
  • prophylactic may be considered as reducing the severity or the onset of a particular condition.
  • “Therapeutic” may also reduce the severity of an existing condition.
  • IL-1 F5 or a variant, derivative, analogue or fragment thereof for use in the present invention may be administered alone but will preferably be administered as a pharmaceutical composition, which will generally comprise a suitable pharmaceutical excipient, diluent or carrier selected depending on the intended route of administration.
  • IL-1 F5 or a variant, analogue or fragment thereof for use in the present invention may be administered to a patient in need of treatment via any suitable route.
  • the precise dose will depend upon a number of factors, including the precise nature of the form of IL-1 F5 to be administered.
  • Routes of administration may include; parenterally (including subcutaneous, intramuscular, intravenous, by means of, for example a drip patch), some further suitable routes of administration include (but are not limited to) oral, rectal, nasal, topical (including buccal and sublingual), infusion, vaginal, intradermal, intraperitoneally, intracranially, intrathecal and epidural administration or administration via oral or nasal inhalation, by means of, for example a nebuliser or inhaler, or by an implant.
  • parenterally including subcutaneous, intramuscular, intravenous, by means of, for example a drip patch
  • some further suitable routes of administration include (but are not limited to) oral, rectal, nasal, topical (including buccal and sublingual), infusion, vaginal, intradermal, intraperitoneally, intracranially, intrathecal and epidural administration or administration via oral or nasal inhalation, by means of, for example a nebuliser or inhaler, or by an implant.
  • composition may also be administered via microspheres, liposomes, other microparticulate delivery systems or sustained release formulations placed in certain tissues including blood.
  • sustained release carriers include semipermeable polymer matrices in the form of shared articles, e.g. suppositories or microcapsules.
  • the IL-1 F5 polypeptide or fragment may be administered directly to the brain or other suitable site of the central nervous system (CNS) in order to deliver the IL-1 F5 to the neural tissue.
  • CNS central nervous system
  • the compositions will be administered in such a way that they are directed to the hippocampus, and in particular can be directed to the microglial cells.
  • the IL-1 F5 polypeptide or fragment may delivered to the brain by means of intracerebroventricular injection (ICV) or through delivery into the CNS using minipumps.
  • ICV intracerebroventricular injection
  • a viral vector may be used to target delivery of the the IL-1 F5 polypeptide or fragment to the brain, CNS or neural tissue.
  • a viral vector will include a construct which contains a gene.encoding for IL-1 F5 or a fragment or analogue thereof.
  • the construct may further contain a promoter which is provided adjacent to the gene and which controls expression of the gene.
  • Viral vector which may be suitable for such delivery and targeting may be nonreplicative herpes simplex type 1 viruses (see for example Poliani et al. (Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther.
  • Semliki Forest virus see Jerusalmi et al. (Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. MoI. Ther. 2003 Dec; 8(6):886-94.) and adenovirus, for example see Braciack et al. (Protection against experimental autoimmune encephalomyelitis generated by a recombinant adenovirus vector expressing the V beta 8.2 TCR is disrupted by co-administration with vectors expressing either IL-4 or -10.J Immunol. 2003 Jan 15;170(2):765- 74.)
  • naked plasmid DNA encoding for IL-1 F5 or fragments and analogues thereof may be directly administered.
  • a particularly preferred nucleotide sequences of the invention is the human IL-1 F5 sequence set forth in SEQ ID NO:1.
  • the sequences of the amino acid encoded by the DNA of SEQ ID NO:1 is shown in SEQ ID NO:2.
  • a DNA sequence can vary from that shown in SEQ ID NO:1 or SEQ ID no:3 and still encode a polypeptide having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 respectively.
  • Such variant DNA sequences can result from silent mutations (e.g., occurring during PCR amplification), or can be the product of deliberate mutagenesis of a native sequence.
  • the invention thus provides isolated DNA sequences encoding polypeptides of the invention, selected from: (a) DNA comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3 (b) DNA encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:4 (c) DNA capable of hybridization to a DNA of (a) or (b) under conditions of moderate stringency and which encodes polypeptides of the invention; (d) DNA capable of hybridization to a DNA of (a) or (b) under conditions of high stringency and which encodes polypeptides of the invention, and (e) DNA which is degenerate as a result of the genetic code to a DNA defined in (a), (b), (c), or (d) and which encode polypeptides of the invention.
  • polypeptides encoded by such DNA sequences are encompassed by the invention.
  • “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley lnterscience Publishers, (1995).
  • stringent conditions may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 5O 0 C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1 % bovine serum albumin/0.1 % Ficoll/0.1 % polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 * SSC (0.75 M NaCI, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 * Denhardt's solution, sonicated salmon sperm DNA (50 mug/ml), 0.1% SDS, and 10% dextran
  • Modely stringent conditions may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above.
  • washing solution and hybridization conditions e.g., temperature, ionic strength and %SDS
  • An example of moderately stringent conditions is overnight incubation at 37°C.
  • the invention thus provides equivalent isolated DNA sequences encoding biologically active forms of the IL-1 F5 polypeptide selected from: (a) DNA derived from the coding region of IL-1 F5; (b) DNA of SEQ ID NO:1 , (c) DNA capable of hybridization to a DNA of (a) or (b) under conditions of moderate stringency and which encodes biologically active IL-1 F5 polypeptides; and (d) DNA that is degenerate as a result of the genetic code to a DNA defined in (a), (b) or (c), and which encodes biologically active IL-1 F5 polypeptides, such as those defined in SEQ ID NO:2.
  • conditions of moderate stringency can be readily determined as defined above.
  • DNA encoding polypeptide fragments and polypeptides comprising inactivated N- glycosylation site(s), inactivated protease processing site(s), or conservative amino acid substitution(s).
  • Embodiments of the invention extend to nucleic acid molecules that are at least 80% identical to the IL-1 F5 sequence as provided in SEQ ID NO:1 or SEQ ID NO:3. Also contemplated are embodiments in which a nucleic acid molecule comprises a sequence that is at least 90%, 91 %, 92%,
  • the percent identity may be determined by visual inspection and mathematical calculation. Alternatively, the percent identity of two nucleic acid sequences can be determined by comparing sequence information using a computer programme. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways using publicly available computer software such as BLAST or ALIGN. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. In one embodiment, the GAP computer program, version 6.0 described by Devereux et al. (Nucl. Acids Res. 12:387, 1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG) is used.
  • the preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non- identities) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National
  • the invention also provides isolated nucleic acids useful in the production of polypeptides.
  • polypeptides may be prepared by any of a number of conventional techniques.
  • a DNA sequence encoding the IL-1 F5 polypeptide, or desired fragment thereof may be subcloned into an expression vector for production of the polypeptide or fragment.
  • the DNA sequence advantageously is fused to a sequence encoding a suitable leader or signal peptide.
  • the desired fragment may be chemically synthesized using known techniques.
  • DNA fragments also may be produced by restriction endonuclease digestion of a full length cloned DNA sequence, and isolated by electrophoresis on agarose gels.
  • oligonucleotides that reconstruct the 5' or 3' terminus to a desired point may be ligated to a DNA fragment generated by restriction enzyme digestion.
  • Such oligonucleotides may additionally contain a restriction endonuclease cleavage site upstream of the desired coding sequence, and position an initiation codon (ATG) at the N-terminus of the coding sequence.
  • the invention encompasses polypeptides and fragments thereof in various forms, including those that are naturally occurring or produced through various techniques such as procedures involving recombinant DNA technology.
  • DNAs encoding IL-1 F5 polypeptides can be derived from SEQ ID NO:1 or SEQ ID NO:3 by in vitro mutagenesis, which includes site-directed mutagenesis, random mutagenesis, and in vitro nucleic acid synthesis.
  • Such forms include, but are not limited to, derivatives, variants, and oligomers, as well as fusion proteins or fragments thereof.
  • polypeptides of the invention include full length proteins encoded by the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:3.
  • a particularly preferred polypeptide comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3.
  • polypeptide fragments of varying lengths. Naturally occurring variants as well as derived variants of the polypeptides and fragments are also provided herein.
  • IL-1 F5 variant as referred to herein means a polypeptide substantially homologous to IL-1 F5, but which has an amino acid sequence different from that of the native IL-1 F5 polypeptide because of one or more deletions, insertions, or substitutions.
  • the variant has an amino acid sequence that preferably is at least 80% identical to an IL-1 F5 polypeptide amino acid sequence, most preferably at least 90% identical.
  • the percent identity may be determined, for example, by comparing sequence information using the GAP computer program, version 6.0 described by Devereux et al. (Nucl. Acids Res. 12:387, 1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG).
  • Variants also include embodiments in which a polypeptide or fragment comprises an amino acid sequence that is at least 90% identical, at least 95% identical, at least 98% identical, at least 99% identical, or at least 99.9% identical to the preferred polypeptide or fragment thereof.
  • Variants include polypeptides that are substantially homologous to the native form, but which have an amino acid sequence different from that of the native form because of one or more deletions, insertions or substitutions.
  • Particular embodiments include, but are not limited to, polypeptides that comprise from one to ten deletions, insertions or substitutions of amino acid residues, when compared to a native sequence.
  • a given amino acid may be replaced, for example, by a residue having similar physiochemical characteristics.
  • conservative substitutions include substitution of one aliphatic residue for another, such as lie, VaI, Leu, or Ala for one another; substitutions of one polar residue for another, such as between Lys and Arg, GIu and Asp, or GIn and Asn; or substitutions of one aromatic residue for another, such as Phe, Trp, or Tyr for one another.
  • Other conservative substitutions e.g., involving substitutions of entire regions having similar hydrophobicity characteristics, are well known.
  • Combinatorial Library Combinatorial library technology provides an efficient way of testing a potentially vast number of different substances for ability to modulate activity of a polypeptide.
  • test substances Prior to or as well as being screened for modulation of activity, test substances may be screened for ability to interact with the polypeptide, e.g. in a yeast two-hybrid system (which requires that both the polypeptide and the test substance can be expressed in yeast from encoding nucleic acid). This may be used as a coarse screen prior to testing a substance for actual ability to modulate activity of the polypeptide.
  • test substance or compound which may be added to an assay of the invention will normally be determined by trail and error depending upon the type of compound used. Typically, from about 0.01 to 100 nM concentrations of putative inhibitor compound may be used, for example from 0.1 to 10 nM. Greater concentrations may be used when a peptide is the test substance.
  • Compounds which may be used may be natural or synthetic chemical compounds used in drug screening programmes. Extracts of plants which contain several characterised or uncharacterised components may also be used.
  • a further class of putative SIGRR inhibitor compounds can be derived from the IL-1 F5 polypeptide and/or a ligand which binds the same.
  • Peptide fragments of from 5 to 40 amino acids, for example from 6 to 10 amino acids from the region of the relevant polypeptide responsible for interaction, may be tested for their ability to disrupt such interaction.
  • candidate inhibitor compounds may be based on modelling the 3- dimensional structure of a polypeptide or peptide fragment and using rational drug design to provide potential inhibitor compounds with particular molecular shape, size and charge characteristics.
  • the substance may be investigated further. Furthermore, it may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals.
  • Mimetics i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals.
  • a substance identified as a modulator of SIGIRR binding and activation may be peptide or non-peptide in nature.
  • Non-peptide "small molecules" are often preferred for many in vivo pharmaceutical uses.
  • a mimetic or mimic of the substance may be designed for pharmaceutical uses.
  • the designing of mimetics to a known pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesise of where it is unsuitable for a particular method of administration, e.g. peptides are not well suited as active agents for oral compositions as they tend to quickly degraded by proteases in the alimentary canal.
  • Mimetic design, synthesis and testing may be used to avoid randomly screening large number of molecules for a target property.
  • the pharmacophore Once the pharmacophore has been found, its structure is modelled to according its physical properties, e.g. stereochemistry, bonding, size and/or charge, using data from a range of sources, e.g. spectroscopic techniques, X-ray diffraction data and NMR. Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used I this modelling process. In a variant of this approach, the three-dimensional structure of the ligand and its binding partner are modelled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this the design of the mimetic.
  • a template molecule is then selected onto which chemical groups which mimic the pharmacophore can be grafted.
  • the template molecule and the chemical groups grafted on to it can conveniently be selected so that the mimetic is easy to synthesise, is likely to be pharmacologically acceptable, and does not degrade in vivo, while retaining the biological activity of the led compound.
  • the mimetic or mimetics found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimisation or modification can then be carried out to arrive at one or more final mimetics for in vivo or clinical testing.
  • a polypeptide, peptide or substance which can modulate the activity of a polypeptide according to the present invention may be provided in a kit, e.g. sealed in a suitable container which protects its contents from the external environment. Such a kit may include instructions for use.
  • Peptides of and for use in the present invention may be modified such that they comprise amide bond replacement, incorporation of non peptide moieties, or backbone cyclisation.
  • cysteine is present the thiol of this residue is capped to prevent damage of the free sulphate group.
  • a peptide of and for use in the present invention may be modified from the natural sequence to protect the peptides from protease attack.
  • a peptide of and for use in the present invention may be further modified using at least one of C and / or N-terminal capping, and / or cysteine residue capping.
  • a peptide of and for use in the present invention may be capped at the N terminal residue with an acetyl group.
  • a peptide of and for use in the present invention may be capped at the C terminal with an amide group.
  • the thiol groups of cysteines are capped with acetamido methyl groups.
  • compositions As described above, the present invention extends to a pharmaceutical composition for the treatment of immune-mediated, autoimmune and neurodegenerative conditions, wherein the composition comprises IL-1F5 or a fragment, derivative, mimetic or analogue thereof.
  • Pharmaceutical compositions for use in accordance with the present invention may comprise, in addition to active ingredient (i.e. IL-1F5), a pharmaceutically acceptable excipient, carrier, buffer stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • active ingredient i.e. IL-1F5
  • a pharmaceutically acceptable excipient, carrier, buffer stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • the precise nature of the carrier or other material will depend on the route of administration, which may be, for example, oral, intravenous, intranasal or via oral or nasal inhalation.
  • IL-1 F5 is preferably administered to an individual in a "therapeutically effective amount", this being sufficient to show benefit to the individual.
  • the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of the condition being treated.
  • Prescription of treatment e.g. decisions on dosage etc, is ultimately within the responsibility and at the discretion of general practitioners, physicians or other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners.
  • the optimal dose can be determined by physicians based on a number of parameters including, for example, age, sex, weight, severity of the condition being treated, the active ingredient being administered and the route of administration.
  • LTP is impaired by LPS administration but maintained by treatment with IL-1 F5.
  • LTP in dentate gyrus was similar in saline treated rats ( ⁇ ) and IL-1 F5 treated ( ⁇ ).
  • LTP is significantly impaired in LPS-treated rats ( ⁇ ) but is maintained in rats treated with LPS and IL-1 F5 (D).
  • the mean slope of the population EPSP evoked by test stimuli delivered at 30 sec intervals before and after tetanic stimulation is shown.
  • Population EPSP slope is expressed as a percentage of the slope recorded in the 5 min immediately prior to tetanic stimulation and values are expressed as means ⁇ standard error of the man of 6 observations. SEMS are included for every 5th response,
  • Figure 2 shows LPS administration affects percentage change in EPSP slope; reversal by treatment with IL-1 F5.
  • a - The mean percentage in EPSP slope in the first 2 min post tetanic stimulation (compared with the 5 min period immediately proceeding tetanus) was decreased in LPS treated rats compared with saline treated rats (n 6).
  • FIG. 4 LPS administration is associated with enhanced immunopositive staining for Ox-6.
  • Magnification is at x40 and scale bar is 10 ⁇ m. The blue colour present in the samples represents the counter stain which was used.
  • Figure 4B represents a typical microglial cell in activated state
  • Figure 5 shows IL-4 concentration is increased in hippocampus following IL-1 F5 treatment.
  • IL-4 concentration was similar to control treated in the hippocampus of rats treated with LPS alone of LPS + IL-1 F5. Values are expressed as pg IL-4/mg tissue corrected for protein and are means ⁇ SEM,
  • Figure 6 shows IL-1 F5 treatment is associated with an increase in
  • IL-1 F5 treatment is associated with an increase in IL-4 mRNA in cultured cortical glial cells.
  • IL-4 mRNA was increased in IL-1 F5 treated cells compared with control treated cells.
  • One sample blot shows that IL-4 mRNA expression was increased in cells treated with IL-1 F5 compared with control treated cells.
  • Mean data was obtained from densitometric analysis and results are expressed as mean ⁇ SEM,
  • Figure 8 shows pre-incubation with an antibody for the novel IL-I receptor SIGIRR is associated with inhibition of IL-1 F5 induced increase in IL-4 in cultured cortical glia.
  • Figure 9 shows IL-1 F5 treatment is associated with an increased surface expression of the novel IL-1 receptor SIGIRR in cultural cortical glial cells.
  • FIG. 10 shows IL-1 ⁇ induced inhibition of LTP is abrogated by IL- 1 F5.
  • LTP in the dentate gyrus is similar in saline treated rats (•), rats treated with IL-1 F5 ( ⁇ ) and rats treated with IL-1 F5 and IL-
  • LTP in the dentate gyrus is significantly impaired in IL- 1 beta treated rats ( ⁇ ) but is maintained in rats co treated with IL- 1 beta and IL 1 F5 (0).
  • the mean slope of the population EPSP evoked by test stimuli delivered at 30 second intervals before and after tetanic stimulation is shown.
  • Population EPSP slope is expressed as a percentage of the slope recorded in the 5 min immediately prior to tetanic stimulation and values are expressed as means ⁇ standard error of the mean of 6 observations. Standard errors are included for every 5th response,
  • Figure 11 shows IL-1 beta administration affects percentage change in EPSP slope; reversal by treatment with IL-1 F5.
  • the mean percentage change in EPSP slope in the first 2 min post tetanic stimulation was decreased in IL-1 beta treated with IL-
  • Figure 12 shows that IL-1 beta administration is associated with an increase in JNK phosphorylation in the hippocampus.
  • One sample immunoblot shows that phosphorylation of JNK (46kDa) was increased in hippocampal tissue prepared from IL-1 beta treated rats (lane 2) compared with tissue prepared from saline-treated rats
  • FIG 13 shows that IL-4 concentration is increased in hippocampus following IL-1 F5 treatment.
  • IL-4 concentration was similar in tissue prepared from IL- 1beta treated rats and rats treated with both IL-1 beta and IL-1 F5 treated rats. Values are expressed as pg IL-4/mg tissue corrected for protein and are means ⁇ SEM,
  • Figure 14 shows that IL-1 F5 treatment is associated with an increase in JAK1 phopsphorylation in hippocappus.
  • Figure 16 shows that IL-1 F5 treatment is associated with an increase in ERK1 and ERK2 phosphorylation in hippocampus.
  • a - One sample immunoblot shows that both ERK 1 and ERK 2 phosphorylation was increased in hippocampal tissue prepared from IL-1 F5 treated rats compared with tissue prepared from saline- treated rats.
  • Figure 17 shows that IL-1 F5 attenuates IL-1 ⁇ induced IL-6 protein and mRNA expression in mouse glia
  • Figure 18 shows that intracerebroventricular injection of IL-1 F5 attenuates LPS induced IL-6 in rat hippocampus
  • Figure 19 shows that intracerebroventricular injection of IL-1 F5 attenuates LPS-induced JNK phosphorylation in rat hippocampus
  • Figure 20 shows that IL-1 F5 suppresses LPS-induced IL-1 ⁇ production by mouse mixed glia cells but not by murine macrophages or dendritic cells
  • Figure 21 shows that IL-1 F5 suppresses LPS-induced IL-1 ⁇ protein production by mixed glia cells but not by macrophages
  • Figure 22 shows that IL-1 F5 induced IL-4 production from murine mixed glial cells but not from dendritic cells, spleen cells or macrophages,
  • Figure 23 shows that IL-1 F5 induces IL-4 protein and mRNA expression in rat mixed glial cells
  • Figure 24 shows that intracerebroventricular injection of rats with IL-
  • Figure 25 shows that IL-4 mediates the IL-1 F5 attenuation of LPS- induced IL-1 ⁇ production from glial cells
  • Figure 26 shows that the attenuation of LPS-induced IL-1 ⁇ production by IL-1 F5 in the hippocampus is mediated through IL-4,
  • Figure 27 shows PPARgamma protein expression levels in primary cultured cortical glia following treatment with IL-1 F5 (24 hour incubation),
  • Figure 28 shows a graph indicating a significant amount of PPARgamma expression induced by IL-1 F5
  • Figure 29 shows a graph which indicates IL-1 beta expression.
  • IL-1 F5 inhibits LPS induced increases in IL- 1 beta expression.
  • Co-treatment with a PPARgamma antagonist reduces this inhibitory effect of IL-1 F5, indicating that PPARgamma plays a role in IL-1 F5 functioning.
  • PPARgamma antagonist is associated with a reduction in IL-1 F5 induced inhibition of IL-1 beta in cultured cortical glia.
  • IL-1 beta concentration was significantly increased in cortical glial cells treated with LPS and this increase was inhibited following co- treatment with IL-1 F5.
  • Pre--treatmnet with a PPAR gamma antagonist abplished this inhibitory affect, indicating that IL-1 F5 PPARgamma activation is neccisary for IL-1 F5 induced inhibition of IL-1 beta,
  • Figure 30 shows the defined nucleotide sequence of human IL-1 F5,
  • Figure 31 shows the defined amino acid sequence of human IL- 1 F5,
  • Figure 32 shows the defined nucleotide sequence of murine IL-1 F5,
  • Figure 33 shows the defined amino acid sequence of murine IL- 1 F5.
  • LPS Lipopolvsaacahride
  • rats were anaesthetised by intraperitoneal (ip) injection of urethane (1.5g/kg; 33% w/v). Depth of anaesthesia was determined by the absence of the pedal reflex and if needed a top up dose of urethane was used (maximum 2.5g/kg). Rats were then injected ip with sterile 0.9% w/v saline or lipopolysaccharide (LPS; 100 ⁇ g/kg in sterile 0.9% w/v saline) from Escherichia coli serotype 0111 :B4 (Sigma, Dorset, UK). Three hours following administration of saline/LPS, rats were assessed for their ability to maintain long-term potentiation (LTP).
  • LPS lipopolysaccharide
  • rats were given an intracerebroventricular (icv) injection.
  • Fur on the scalp was clipped and the head was positioned in a head holder in a stereotaxic frame (ASI Instruments).
  • a midline incision was made with a scalpel and the skin pulled back to reveal the skull.
  • the peristeum was scraped clear and a Bregma and Lambda were identified.
  • a dental drill was used to form a small hole in the skull 2.5mm posterior and 0.5mm lateral, to Bregma, though which agents could be injected.
  • Rats were administered IL-1 F5 (3 ⁇ g/ml; recombinant E.coli expressed) and 5 minutes later were administered saline or LPS by ip injection.
  • mice were assessed for their ability to sustain LTP 3 hours after injection.
  • rats were given IL-1 beta (3.5ng/ml; R& D systems, UK) and IL-1 F5 (3 ⁇ g/ml) icv and in this case were assessed for their ability to maintain LTP after 30minutes.
  • Bipolar stimulating electrodes and unipolar recording electrodes were used in this study.
  • the stimulating electrode was placed on the surface of the brain, 4.4mm lateral to lambda.
  • the recording electrode was placed on the surface of the brain 2.5mm lateral and 3.9mm posterior to Bregma.
  • the positions of the stimulating and recording electrodes were carefully monitored as they were lowered in increments through the cortical and hippocampal layers into the perforant path and granule cell layer of the dentate gyrus respectively, until the characteristic perforant path granule cell synapse response was observed.
  • the depth of electrodes was finely adjusted so as to maximize the response.
  • EPSP population field post-synaptic potential
  • the evoked response was transmitted via a pre-amplifier (DAM 50;
  • test shocks at 1/30 sec were recorded for a 10min control period to establish baseline recordings. This was followed by a delivery of 3 trains of stimuli (250 Hz for 200 msec) at 30 second intervals. Recording at test shock frequency then resumed for 40 minutes.
  • Rats were killed by cervical dislocation and decapitation. The brains were rapidly removed. One half of the brain was coated in OCT compound (Sakura Tissue-Tek, Netherlands), immersed in liquid N2 and stored at - 80°C until sections were prepared. From the remaining half of the brain the hippocampus and cortex were quickly dissected free on ice.
  • OCT compound Sakura Tissue-Tek, Netherlands
  • Freshly dissected tissue was sliced bidirectionally to a thickness of 350 ⁇ m using a Mcllwain tissue chopper (Mickle Laboratory Engineering Co., Surrey, UK). Tissue was added in Eppindorf tubes containing 1 ml Krebs solution (composition in mM: NaCI 136, KCi 2.54, KH 2 PO 4 1.18, MgSO 4 7H 2 O 1.18, NaHCO 3 16, glucose 10) with added CaCI2 (2mM final concentration). Tissue slices were vortexed and allowed to settle, before being washed twice more in this Krebs solution. The slices were rinsed with Krebs solution containing 2mM CaCI 2 containing 10% dimethyl sulphoxide and stored at -80°C until required for later analyses.
  • Protein quantification was assessed according to Bradford (1976). Standards were prepared from a 200 ⁇ g/ml stock solution of bovine serum albumin (BSA; Sigma Dorset, UK). A range of standards was prepared from this solution from 200 ⁇ g/ml to 3.125 ⁇ g/ml. Standards were added in duplicate to the 96-well plate and Bio-Rad dye reagent concentrate (40 ⁇ l; Bio-Rad, Hertfordshire, UK) was added to both standards and samples. Absorbance was measured at 630nm using a 96-well plate reader (Labsystems Multiskan RC, UK). A regression line was plotted (GraphPad Prism, US) and the concentration of protein was calculated and converted to mg protein/ml.
  • BSA bovine serum albumin
  • IL-1 beta concentration was assessed by Enzyme Linked Immunosorbent Assay (ELISA).
  • ELISA Enzyme Linked Immunosorbent Assay
  • 96-well plates Nunc-lmmuno plate with MaxiSorp surface
  • capture antibody 100 ⁇ l; 1 ⁇ g/ml; goat anti-rat IL-1 ⁇ in PBS (137mM NaCI, 2.7mM KCI, 8.1 mM Na 2 HPO 4 and 1.5mM KH 2 PO 4 pH7.3; R&D systems, Minneapolis, USA) and incubated overnight at room temperature (RT).
  • a wash buffer of PBS containing 0.05% Tween-20, pH 7.4 was used to wash the plate 3 times and a blocking buffer (300 ⁇ l; PBS containing 1% BSA, 5% sucrose and 0.05% NaN3) was added to the wells and the plates were incubated at room temperature for 1 hour.
  • Standards were prepared from rat recombinant IL-1beta (R&D systems Minneapolis, USA) diluted in PBS containing 1% BSA. Plates were washed 3 times in wash buffer and 100 ⁇ l of standards and samples were incubated for 2 hours at RT.
  • IL-4 concentration was assessed by Enzyme Linked Immunosorbent Assay (ELISA).
  • 96-well plates Nunc-lmmuno plate with MaxiSorp surface
  • capture antibody 100 ⁇ l; 2 ⁇ g/ml; monoclonal mouse anti- rat IL-4 in PBS; R&D systems, Minneapolis, USA
  • a wash buffer of PBS containing 0.05% Tween-20, pH 7.4 was used to wash the plate 3 times and a blocking buffer (300 ⁇ l; PBS containing 1 % BSA, 5% sucrose and 0.05% NaN3) was added to the wells and the plates were incubated at RT for 1 hour.
  • the plates were washed 3 times in wash buffer and streptavidin horseradish peroxidase conjugate (100 ⁇ l; 1 :200 dilution in PBS containing 1 % BSA; R&D systems, Minneapolis, USA) was added and incubation continued at RT for 1 hour.
  • the plates were washed 3 times with wash buffer and substrate solution (1 OO ⁇ l; 1 :1 dilution Reagent A (H 2 O 2 ) and Reagent B (tetramethylbenzidine); R&D systems, Minneapolis, USA) was added to the well.
  • the plates were incubated in the dark for 40 minutes, creating a colour change to blue.
  • a stop solution (1 M H 2 SO 4 ; 50 ⁇ l) was added to each well.
  • the plates were read at 450nm on a 96-well plate reader (Labsystems Multiskan RC). A standard curve was produced and results were expressed as pg IL-4/mg tissue corrected for protein (see section 2.5) or as pg/ml supernatant for in vitro experiments.
  • Coated coverslips were air-dried, placed in 24-well plates (Greiner, Austria) and stored at 4°C until required.
  • GNa were isolated from cerebral cortices of Wistar rats 1 day postpartum (BioResources Unit, Trinity College, Dublin). Rats were decapitated and cortices dissected as described above. Cortices were placed in 3 ml Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum (Gibco, UK), penicillin (100U/ml; Gibco, UK) and streptomycin (100U/ml; Gibco, UK). Tissue was triturated (x7), passed through a sterile nylon mesh filter and centrifuged (250Og for 3 min at 20 0 C). The pellet was resuspended in DMEM.
  • DMEM Dulbecco's Modified Eagle Medium
  • Resuspended glia were placed on the centre of each coverslip (65 ⁇ l per coverslip) and allowed to adhere to the glass coverslip for 2 hours in a humidified incubator containing 5% CO 2 : 95% air at 37°C before 400 ⁇ l of pre-warmed DMEM was added to each well. Cells were grown for 10 days prior to treatment and media replaced every 3 days.
  • IL-1 F5 was diluted to a stock concentration of 300 ⁇ g/ml in PBS and stored at -80 0 C.
  • IL-1 F5 was diluted to a final concentration of 3 ⁇ g/ml in media. Cells were treated with IL-1 F5 for 24 hours.
  • Recombinant rat IL-1 beta (R&D Systems, USA) was prepared as a stock solution of 1 ⁇ g/ml in sterile PBS and used at a final concentration of 5ng/ml in media. Cells were treated with IL-1 beta for 24 hours.
  • An antibody to the SIGIRR receptor (anti-SIGIRR; R&D Systems, Minneapolis, USA) was diluted to a concentration of 100 ⁇ g/ml in PBS. Working concentrations of 20 ⁇ g/ml were prepared in media. Cells were incubated in anti-SIGIRR for a period of 4 hours.
  • Coverslips were washed 3 times in PBS and secondary antibody was added (1 OO ⁇ l; 1 :100 dilution; anti-goat IgG conjugated to FITC; Sigma, UK) for 1 hour at room temperature. Coverslips were washed several times in distilled H2O (dH20), before being mounted onto microscope slides using a mounting medium for fluorescence (Vector, USA) and the perimeter of each coverslip was sealed using nail varnish. Mounted coverslips were viewed under x40 magnification by fluorescence microscopy (Leitz Orthoplan Microscope, Germany) using Improvision software (Improvision, UK). Cells were observed at excitation, 490nm; emission, 520nm for FITC labelled antibodies.
  • Frozen cryostats sections were thawed at room temperature. Sections were fixed using ice-cold absolute ethanol for 10 min, washed using TBS (containing in mM: 137mM NaCI, 2.7mM KCI, 8.1 mM Na2HPO4 and 1.5mM KH2PO4 pH 7.3; R&D systems, Minneapolis, USA) and then blocked using as solution of 10% normal goat serum (NGS; Vector Laboratories, USA) containing 4% BSA in TBS . Sections were incubated overnight in a humidified chamber at 4°C in the presence of OX-6 antibody (10 ⁇ l/ml; 1 :100 in TBS; Serotec, UK).
  • TBS normal goat serum
  • Sections were then washed in TBS and incubated in the presence of a secondary antibody, anti-mouse IgG (1 :200 in TBS; Sigma, Dorset, UK). Washing in PBS was repeated and sections were placed in avidin-biotin-horseradish peroxidase solution, diluted in TBS for 1 hour (Vectastain elite ABC kit, Vector Laboratories, USA) and then reacted with 3,3'-diaminobenzidine (DAKO Corporation, USA) and H 2 O 2 for colour development. The reaction was terminated by washing the sections in double distilled H 2 O, and positively stained cells were visualized under the light microscope at X4 and X40 magnification.
  • a secondary antibody anti-mouse IgG
  • sample buffer 0.5M Tris-Hcl pH 6.8; 20% glycerol (w/v); 2% SDS (w/v); 5% mercaptoethanol (v/v); 0.05% bromophenol blue (w/v)
  • glycerol w/v
  • SDS w/v
  • 5% mercaptoethanol v/v
  • bromophenol blue w/v
  • Polyacrylamide gels (1 mm thick) were prepared with either a monomer concentration of 10% or 12% overlaid with 4% stacking gel, between 10cm wide glass plated, mounted on an electrophoresis unit (Sigma Techware, Dorset, UK' Laemmli, 1970). Electrode running buffer (25mM TrisObase; 20OmM glycine; 17mM SDS) was added to the upper and lower reservoirs of the unit. Samples were loaded into the wells using a Hamilton MicroLiter syringe (10 ⁇ l per well). A pre-stained molecular weight marker (5 ⁇ l; Sigma, Dorset, UK or Santa Cruz, California, USA) was also loaded. A 32mA current was passed through the unit in order to separate proteins, according to their molecular weight. The current was switched off when the blue dye band reached the bottom of the gel.
  • nitrocellulose membrane was blocked for non-specific binding and then probed with an antibody raised against the appropriate protein.
  • the membrane was then washed and incubated with horseradish peroxidase (HRP) conjugated secondary antibody.
  • HRP horseradish peroxidase
  • a chemiluminescent detection agent was added and the membrane was exposed to 5 by 7 inch photographic film (Hyperfilm ECL, Amersham, Buckinghamshire, UK) and developed using a Fuji X-ray processor.
  • Non-specific binding was blocked by incubating nitrocellulose membranes overnight at 4°C in Tris-buffered saline(TBS 10ml per membrane; TBS; 2OmM Tris-HCL; 15OmM NaCI; pH7.6) containing 5% BSA. Membranes were washed 3 times for 15 minutes in TBS-T.
  • the primary antibody used was a mouse monoclonal IgG antibody raised against a peptide corresponding to a short sequence of JNK1 human origin, which identifies the phosphorylated form of JNK (10ml; 1 :300 dilution in TBS containing 0.1% BSA; Santa Cruz, California, USA).
  • Membranes were incubated in the presence of the primary antibody for 2 hours at RT, and then washed for 15 minutes 3 times in TBS-T.
  • the secondary antibody (10ml; 1 :600 dilution; goat anti-mouse HRP in TBS containing 0.1 % BSA; Sigma, Dorset, UK) was added and incubation proceeded for 1 hour at room temperature.
  • Membranes were washed 3 times for 15 minutes with TBS-T, Supersignal (Pierce, Illinois, USA) was added for 5 minutes after which membranes were exposed to photographic film for 1 second in the dark, after which time the film was developed.
  • Non-specific binding was blocked by incubating nitrocellulose membranes overnight at 4 0 C in Tris-buffered saline (10ml; TBS; 2OmM Tris-HCI;
  • Membranes were incubated in the presence of the primary antibody for 2 hours at room temperature, and then washed for 15 min 3 times in TBS-T.
  • the secondary antibody (10ml; 1 :600 dilution; rat anti-goat HRP in TBS containing 0.1 % BSA; Sigma, Dorset, UK) was added and incubation proceeded for 1 hour at RT.
  • Membranes were washed for 15min 3 times with TBS-T.
  • Supersignal (Pierce, Illinois, USA) was added. Samples were incubated for 5 minutes after which time membranes were exposed to photographic film for 1 sec in the dark, after which time the film was developed.
  • ERK phosphorylation was assessed in whole-cell lysate using a rat monoclonal IgGI antibody raised against a peptide corresponding to a sequence of short sequence of ERK of mouse origin, which recognizes the phosphorylated form of ERK (10ml; 200 ⁇ g/ml; 1 :200 dilution in TBS-T containing 1 % BSA; Santa Cruz, USA). Blotting proceeded as described above.
  • the primary antibody used was a mouse monoclonal IgG antibody corresponding to amino acid sequence mapping the terminus of actin (10ml; 1 :200 dilution in TBS containing 0.1% BSA; Santa Cruz, California, USA). Membranes were incubated for 2 hours in the presence of the primary antibody and then washed 3 times for 15 min with TBS-T.
  • the secondary antibody (10ml; 1 :500 dilution; goat anti- mouse IgG HRP in TBS containing 0.1% BSA; Sigma, Dorset, UK) was added and incubation resumed for 1 hour at room temperature. Membranes were washed for 15 minutes, 3 times in TBS-T. Supersignal (Pierce, Illinois) was added and membranes were incubated for 5 minutes and the membranes were exposed to film and developed.
  • TRI reagent Sigma, Dorset, UK
  • RNA pellets were washed with 75% ethanol (Sigma, Dorset, UK), allowed to air dry and resuspended in DEPC treated water.
  • RNA samples were run on a 1% (w/v) agarose gel to ensure RNA was intact and had not been degraded.
  • Agarose gel was prepared in 1X Tris borate EDTA (TBE) buffer (100ml; 0.08 M Tris; 0.04M Boric acid; 1 mM EDTA; pH 8.3). Ethidium Bromide (EtBr; Sigma, Dorset, UK) was added to give a final concentration of 0.5 ⁇ g/ml.
  • RNA samples were mixed with 3.5 ⁇ l of H2O and 1 ml X6 gel loading buffer (60% (w/v) glycerol, 0.4% (w/v) bromophenol blue) in preparation for gel electrophoresis. Samples were loaded onto gels and RNA was separated by application of a 90 V voltage to the gel apparatus. Migration of the bromophenol blue was monitored and the voltage was switched off when the blue dye band reached the bottom of the gel. The gel was visualized under UV light.
  • TBE Tris bo
  • RNAse-free DNAse I (Invitrogen, USA) and 10X DNAse 1 reaction buffer at 1 unit/ ⁇ g of RNA for 15 min at RT. EDTA solution was then added to inactivate the DNAse was the samples were incubated at 65°C for 10 minutes.
  • Equal amounts of cDNA were used for PCR amplification using Superscript Il RNASE reverse transcriptase enzyme (Invitrogen, UK). 1 ⁇ g of sample RNA was mixed with 1 ⁇ l of Oligo dT Primer (Invitrogen, UK) and 1 ⁇ l of dNTP mix (Promega, UK). The sample was incubated at 65°C for 5 min after which it was removed to ice. 5X reaction buffer (4 ⁇ l), 0.1 M - -dithiothreitol (DTT; 2 ⁇ l) and RNAse Inhibitor (1 ⁇ l; Promega, USA) was added to the reaction mixture and the reaction was heated to 42°C then Superscript reverse transcription enzyme was added (1 ⁇ l). The reaction was incubated at 42°C for 50 min for cDNA synthesis and then at 75°C for 10 minutes to inactivate the reverse transcription.
  • Superscript Il RNASE reverse transcriptase enzyme Invitrogen, UK.
  • a mastermix PCR solution was prepared (25 ⁇ l; 2.5 ⁇ l 10X reaction, 2.5 ⁇ l MgCI2, 1 ⁇ l dNTP mix (Promega, USA) 1 ⁇ l of upstream and downstream primers, 13 ⁇ l double distilled (ddH2O), 0.5 ⁇ l of Taq polymerase). 2.5ul of sample was added to the mastermix and PCR was run with a total of 35 cycles. Primers were pre-tested through an increasing number of cycles in order to obtain RT-PCR products in the exponential range.
  • primers generated IL-4 PCR products of 352bp and beta-actin PCR products of 360 bp. Equal volumes of PCR product from each sample was loaded onto 1.5% agarose gels, bands were separated by application of 90V, photographed and quantified using densitometry.
  • Example 1 - LPS administration is associated with impairment in LTP but abrogated with IL-1 F5 treatment
  • LTP was similar in saline treated rats to those treated with IL-1 F5 in perforant path granule cell synapses was markedly attenuated in rats injected with LPS ( * p ⁇ 0.001 ; ANOVA; Figure 1 ).
  • Example 2 - LPS administration is associated with an increase in the concentration of IL-1 beta in the hippocampus It has been shown that the LPS-induced inhibition of LTP is coupled with an increased IL-1 beta concentration in the hippocampus and the data presented in Figure 3 support these findings.
  • Example 3 - LPS administration is associated with an increase in OX-6 positive staining in the hippocampus
  • FIG. 5 shows that IL-4 concentration was significantly increased in hippocampal tissue prepared from IL-1 F5 treated rats (186.12 ⁇ 8.36; * p ⁇ 0.05; Figure 5) and IL-4 concentration was similar in control-treated rats and rats treated with LPS alone or with IL-1 F5.
  • Example 5 - IL-4 protein concentration and mRNA is increased in cultured cortical glial cells following treatment with IL-1 F5
  • Past studies have indicated that IL-4 is produced by glia and to confirm this, glial cells were prepared and treated with and without IL-1 F5.
  • Analysis of the supernatants, prepared from glial cells indicate that IL-1 F5 significantly increased IL-4 concentration (22.79 ⁇ 2.54 compared with 9.58 ⁇ 1.319; * p ⁇ 0.05; students unpaired t test; Figure 6).
  • Figure 7 shows that IL-1 F5 has the ability to increase IL-4 mRNA.
  • Example 6 The IL-1 F5 mediated increase in IL-4 is abrogated following treatment with anti-SIGIRR
  • SIGIRR is known to be distributed in the brain.
  • Example 7 - IL-1 F5 treatment is associated with an increase in SIGIRR expression in cultured cortical alia
  • FIG. 9 shows that SIGIRR is expressed in glia and that treatment of cultured cortical glia with IL-1 F5 results in an increase in SIGIRR expression when compared to controls.
  • Example 8 - IL-1 beta administration is associated with impairment in LTP but is restored by treatment with IL-1 F5
  • IL-1 F5 mediated through its ability to initiate IL-4 production, therefore it must be predicted that IL-4 will mimic the effects of IL-1 F5.
  • Previous studies have indicated that many actions of IL-1 beta are inhibited by IL-4 (Nelms et al., 1990) and the evidence suggests that the ability of IL-4 to downregulate IL-1 R1 expression may be responsible for these effects (Nolan et al., 2004).
  • IL-1 F5 mediates the effects of IL-1 F5
  • IL-1 F5 will mimic the effects of IL-4 in blocking IL-1 beta induced inhibition of LTP.
  • Figure 10 shows that while LTP was attenuated in IL-1 beta treated rats, IL-1 F5 had the ability to abrogate this effect so that the change in EPSP slope induced by tetanic stimulation in control-treated rats was similar to that in rats treated with IL-1 beta in combination with IL-1 F5.
  • Example 9 - IL-1beta administration is associated with an increase in JNK in the hippocampus
  • IL-4 concentration is increased in the hippocampus following IL-1 F5 treatment Hippocampal tissue was prepared from these rats was assessed for IL-4 concentration by ELISA and the findings demonstrate that the mean cytokine concentration was significantly increased in hippocampal tissue prepared from IL-1 F5-treated rats, compared with control-treated rats (p ⁇ 0.05; ANOVA; Figure 13), while the concentration was similar in tissue prepared from rats treated with LPS and those treated with IL-1 beta and IL-1 F5 ( Figure 13).
  • Example 10 - IL-1 F5 administration is associated with an increase in JAK1 and STAT6 phosphorylation in the hippocampus
  • the data represented in figures 15 and 16 indicate there was a significant increase in JAK1 phosphorylation in hippocampal tissue prepared from IL-1 F5 treated rats (222.83 ⁇ 61.51 arbitrary units), compared with control treated rats (106.45 ⁇ 6.69 arbitrary units; p ⁇ 0.05; students unpaired t test; Figure 14).
  • Example 11 - IL-1 F5 treatment is associated with an increase in ERK phosphorylation in the hippocampus
  • Results indicate an increase in both ERK1 and ERK2 in hippocampal tissue prepared from IL-1 F5 treated rats.
  • Densitometric analysis revealed that ERK2 phosphorylation was significantly increased in hippocampal tissue prepared from IL-1 F5 treated rats (9.48 ⁇ 0.98 arbitrary units) compared with control treated rats (4.00 + 1.24; * p ⁇ 0.05; students unpaired t test; * p ⁇ 0.05; students unpaired t test; Figure 16).
  • Example 12 - IL-1 F5 attenuates IL-1 ⁇ induced IL-6 protein and mRNA expression in mouse alia
  • glial cell cultures were prepared from C57BL/6 mice and treated with IL-1 ⁇ (5 ng/ml) alone or in the presence of IL-1 F5 (3 ⁇ g /ml).
  • B) Cells were lysed and IL-6 mRNA expression was determined by RT-PCR. Results are expressed as arbitrary units relative to ⁇ -actin. ** p ⁇ 0.01 , *** p ⁇ 0.001 IL-1 ⁇ versus control; + p ⁇ 0.05, +++ p ⁇ 0.001 , IL-1 ⁇ versus IL-1 ⁇ + IL-1 F5 by ANOVA; n 6. Results
  • Example 13 Intracerebroventricular injection of IL-1 F5 attenuates LPS induced IL-6 in rat hippocampus
  • Example 15 - IL-1 F5 suppresses LPS-induced IL-1 ⁇ production by mouse mixed alia cells but not by murine macrophages or dendritic cells
  • Example 16 - IL-1 F5 suppresses LPS-induced IL-1 ⁇ protein production bv mixed alia cells but not by macrophages
  • Rat mixed glia cells or the murine macrophage cell line J774 cells were cultured with medium only or LPS (100 ng/ml) alone or in the presence of IL-1 F5 (3 ⁇ g/ml). After 24 hours supernatants were removed and IL-1 ⁇ concentrations determined by ELISA. *** p ⁇ 0.001 , LPS versus control; +++ p ⁇ 0.001 LPS versus LPS + IL-1 F5 by ANOVA. Results
  • Example 18 - IL-1 F5 induces IL-4 protein and mRNA expression in rat mixed glial cells
  • Rat mixed glial cells were cultured for 24 hours with medium only (Con) or IL-1 F5 (3 ⁇ g/ml).
  • (B) Cells were lysed and IL-4 mRNA expression was determined by RT-PCR. Results are expressed as arbitrary units relative to ⁇ -actin. * , p ⁇ 0.05, * *p ⁇ 0.01 IL-1 F5 versus control by unpaired Students-t test; n ⁇ Results
  • Example 20 - IL-4 mediates the IL-1 F5 attenuation of LPS-induced IL-1 ⁇ production from glial cells
  • Example 21 The attenuation of LPS-induced IL-1 ⁇ production by IL-1 F5 in the hippocampus is mediated through IL-4
  • mice received an intracerebroventricular injection of IL-1 F5 (30 ng/ml) or vehicle only followed 15 minutes later by an intraperitoneal injection of LPS (200 ⁇ g/kg) or vehicle only.
  • Mice were sacrificed after 3 hours, hippocampal tissue was prepared, homogenized and IL-1 ⁇ concentrations determined by ELISA.
  • *** p ⁇ 0.001 , LPS versus control, +++p ⁇ 0.001 , LPS versus LPS + IL-1 F5, X p ⁇ 0.05, IL-4 V" versus wiltype mice by ANOVA; n 6)
  • Example 22 Effect of PPAR ⁇ amma expression on IL-1 F5 mediated inhibition of LPS induced IL-1 beta in glial cells
  • GHa cortical glia cells were prepared as follows. GHa were isolated from cerebral cortices of Wistar rats 1 day postpartum (BioResources Unit, Trinity College, Dublin). Rats were decapitated and cortices dissected. Cortices were placed in 3ml Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum (Gibco, UK), penicillin (100U/mI; Gibco, UK) and streptomycin (100U/ml; Gibco, UK). Tissue was triturated (x7), passed through a sterile nylon mesh filter and centrifuged (250Og for 3 min at 20 0 C). The pellet was resuspended in DMEM.
  • DMEM Dulbecco's Modified Eagle Medium
  • Resuspended glia were placed on the centre of each coverslip (65 ⁇ l per coverslip) and allowed to adhere to the glass coverslip for 2 hours in a humidified incubator containing 5% CO2: 95% air at 37°C before 400 ⁇ l of pre-warmed DMEM was added to each well.
  • Cells were grown for 10 days prior to treatment and media replaced every 3 days.
  • Cell were treated with LPS (lOOng/ml), IL-1 F5 (3 ⁇ g/ml), GW9962 (20 ⁇ M) or combinations of these treatments. Twenty four hours later, supernatant was collected for analysis of IL-1 beta and cells were harvested for analysis of PPARgamma expression by gel electrophoresis and immunoblotting.
  • IL-1 beta was analysed by ELISA as previously described (Barry et al., J
  • PPARgamma was assessed by standard procedures (Barry et al., 2005) using anti-rabbit polyclonal PPAR ⁇ (10ml; 1 :400 dilution in TBS containing 0.1% BSA; Calbiochem, USA) as the primary and anti-rabbit IgG linked antibody (1 :1000 dilution in TBS containing 0.1 % BSA; Santa Cruz, USA) as the secondary antibodies.
  • Figure 28 shows that PPARgamma protein expression was found in primary cultured cortical glia following treatment with IL-1 F5 (24 hour incubation).
  • Figure 29 shows that the level of expression of PPARgamma expression induced by IL-1 F5 is significant, and
  • Figure 30 shows that IL- 1 F5 inhibits LPS induced increase in IL-1 beta expression.
  • co- treatment with a PPARgamma antagonist reduces this inhibitory effect of IL-1 F5, indicating that PPARgamma may play a role in IL-1 F5 functioning.
  • JNK c-Jun N terminal kinase
  • microglial activation was assessed, since the most likely source of the LPS-induced increase in IL-1 beta concentration is activated microglia. It was demonstrated that the marker for microglia activation, the MHCII was clearly upregulated in hippocampal sections prepared from LPS treated rats and that IL-1 F5 attenuated this effect.
  • IL-4 has been the subject of extensive research, as it emerges that it plays a pivotal role in modulating the inflammatory process.
  • IL-4 has been shown to reverse impairment of LTP and lead to increase in the release of anti-inflammatory agents such as TGF- beta.
  • Activation of a number of signalling pathways leads to IL-4 influencing gene expression - phosphatidylinositol-3 kinase, phosphorylation of insulin receptor substrates by IL-4R ⁇ chain, activation of Ras/MAP kinases including ERK, and activation of the JAK/STAT pathway.
  • Binding of IL-4 to its receptor results in the translocation of STAT6 to the nucleus. Once in the nucleus, STAT6 binds to STAT-binding elements to activate gene transcription
  • Genes induced by IL-4 include IL-4R ⁇ , IL-1 ra, IL-4 and MHC II.
  • IL-4 has the ability to inhibit activation of genes associated with inflammation including IL-1 ⁇ , IL-12, TNF-alpha and iNOS which generates nitric oxide.
  • IL-4 binding results in the suppression of macrophage activity and the differentiation of T-helper cells towards a Th2 cell phenotype further promoting anti-inflammatory activity.
  • Once activated IL-4 initiates a series of signalling events leading to the activation of protective transcription factors. This sequencing events involves activation of the janus activates kinases (JAKs) and signal transducers and activation of transcription (STATs).
  • IL-1 F5 exerts its anti-inflammatory effect by increasing IL-4 concentration in the hippocampus and the evidence presented supports this. In addition to demonstrating an increase in IL-4 concentration in the hippocampus of rats treated with IL-1 F5, it can be reported that IL-1 F5 acts to increase IL-4 mRNA and IL-4 protein in glial cells.
  • IL-1 F5 A specific anti-inflammatory action of IL-1 F5 has been identified.
  • IL-1 F5 is shown to be a Iigand for SIGIRR, and downstream signalling from SIGIRR activation results in an anti-inflammatory effect. Further, IL-1 F5 upregulates IL-4 and IL-4 dependent signalling pathways in the brain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)

Abstract

L'invention concerne la découverte selon laquelle l'IL-1 F5 (IL-1 delta) et les polypeptides dérivés de celle-ci se lient au récepteur SIGIRR, cette interaction de liaison servant à moduler une réaction immunitaire par stimulation de la production de la cytokine IL-4. Ladite liaison induit une réaction immunitaire anti-inflammatoire. Il a également été démontré que le récepteur PPARgamma s'avère être un médiateur clé dans la signalisation en aval à partir du récepteur SIGIRR après activation par le ligand IL-1 F5. La modulation de la réaction immunitaire se produit après liaison du récepteur SIGIRR par l'IL-1 F5 dans des tissus neuronaux et selon des méthodes pour le traitement de maladies neurodégénératives.
PCT/IE2006/000103 2005-09-21 2006-09-21 Compositions et methodes associees a la modulation d'une reaction a mediation immunitaire WO2007034465A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE2005/0627 2005-09-21
IE20050627 2005-09-21

Publications (2)

Publication Number Publication Date
WO2007034465A2 true WO2007034465A2 (fr) 2007-03-29
WO2007034465A3 WO2007034465A3 (fr) 2007-11-29

Family

ID=37872238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2006/000103 WO2007034465A2 (fr) 2005-09-21 2006-09-21 Compositions et methodes associees a la modulation d'une reaction a mediation immunitaire

Country Status (1)

Country Link
WO (1) WO2007034465A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177595A1 (fr) * 2011-06-21 2012-12-27 Oncofactor Corporation Compositions et méthodes pour la thérapie et le diagnostic du cancer
WO2019081591A1 (fr) 2017-10-24 2019-05-02 Humanitas Mirasole S.P.A. Cellules nk et lymphocytes t et leurs utilisations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0879889A2 (fr) * 1997-05-19 1998-11-25 Smithkline Beecham Corporation Un membre de la famille de l'interleukine-1,iL-1 delta
WO1999032626A1 (fr) * 1997-12-23 1999-07-01 Immunex Corporation Adn et polypeptides sigirr
WO2000020595A1 (fr) * 1998-10-08 2000-04-13 Zymogenetics, Inc. Homologues de l'interleukine-1
WO2000071719A1 (fr) * 1999-05-20 2000-11-30 Hyseq, Inc. Substances liees a l'interleukine-1 hy2 (il-1 hy2) et procedes
US20050058625A1 (en) * 1998-01-09 2005-03-17 Immunex Corporation IL-1 delta DNA and polypeptides
WO2005084696A1 (fr) * 2004-03-08 2005-09-15 Universita'degli Studi Di Milano Procedes et agents permettant de maitriser l'inflammation intestinale et l'immunite mucosale au moyen d'agents interagissant avec tir8/sigirr

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0879889A2 (fr) * 1997-05-19 1998-11-25 Smithkline Beecham Corporation Un membre de la famille de l'interleukine-1,iL-1 delta
WO1999032626A1 (fr) * 1997-12-23 1999-07-01 Immunex Corporation Adn et polypeptides sigirr
US20050058625A1 (en) * 1998-01-09 2005-03-17 Immunex Corporation IL-1 delta DNA and polypeptides
WO2000020595A1 (fr) * 1998-10-08 2000-04-13 Zymogenetics, Inc. Homologues de l'interleukine-1
WO2000071719A1 (fr) * 1999-05-20 2000-11-30 Hyseq, Inc. Substances liees a l'interleukine-1 hy2 (il-1 hy2) et procedes
WO2005084696A1 (fr) * 2004-03-08 2005-09-15 Universita'degli Studi Di Milano Procedes et agents permettant de maitriser l'inflammation intestinale et l'immunite mucosale au moyen d'agents interagissant avec tir8/sigirr

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177595A1 (fr) * 2011-06-21 2012-12-27 Oncofactor Corporation Compositions et méthodes pour la thérapie et le diagnostic du cancer
WO2019081591A1 (fr) 2017-10-24 2019-05-02 Humanitas Mirasole S.P.A. Cellules nk et lymphocytes t et leurs utilisations

Also Published As

Publication number Publication date
WO2007034465A3 (fr) 2007-11-29

Similar Documents

Publication Publication Date Title
JP6546232B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP6514259B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
Hu et al. IL-17RC is required for IL-17A–and IL-17F–dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis
McDaniel et al. Emerging roles for noncanonical NF-κB signaling in the modulation of inflammatory bowel disease pathobiology
US8187596B1 (en) Method of treating asthma or allergy by administering an IL-33 receptor antibody
JP4902961B2 (ja) 哺乳動物サイトカインの用途；関連試薬
JP5822822B2 (ja) Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用
WO2006023791A2 (fr) Procedes et compositions pour le traitement d'inflammation allergique
Lamacchia et al. Endogenous IL-1α is a chromatin-associated protein in mouse macrophages
EP3194431B1 (fr) Interleukine-38 tronquée au niveau de l'extrémité n
US20090305985A1 (en) Immunomodulatory Agents For Treatment of Inflammatory Diseases
Pathak et al. Autoimmune inner ear disease patient–associated 28-kDa proinflammatory IL-1β fragment results from caspase-7–mediated cleavage in vitro
JPH11177A (ja) ＩＬ−１ファミリーの新規メンバー、ＩＬ−１δ
Ackerman et al. Human eosinophil lysophospholipase (Charcot-Leyden crystal protein): molecular cloning, expression, and potential functions in asthma
WO2007034465A2 (fr) Compositions et methodes associees a la modulation d'une reaction a mediation immunitaire
US20120135401A1 (en) Methods and Compounds for the Diagnosis of Inflammatory Disease and Identification of Pharmacological Agents Useful in the Treatment of Inflammatory Disease
US20060073572A1 (en) Cytokine structurally related to IL-17
US20210346462A1 (en) Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
WO2014181273A1 (fr) Procédés de traitement d'une affection intestinale inflammatoire
EP2913060A1 (fr) Inhibition de l'interaction de récepteur de fractalkine pour le traitement de la dermatite atopique
Cruz Functional Regulation of Interleukin-17 Receptor Signaling
DE60123235T2 (de) Regulation einer nf-at interagierenden proteinvariante nip 45
Piras Identification of potential disease biomarkers in tissues and saliva by an integrated Top-down and Bottom-up proteomic approach
Niedbala et al. EXTENDED REPORT Interleukin-27 attenuates Collagen-induced arthritis
Dragon Molecular Signaling Mechanisms and Effector Functions Of the Interleukin-17 Receptor in Human Airway Smooth Muscle Cells and Polymorphonuclear Neutrophils

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06796045

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06796045

Country of ref document: EP

Kind code of ref document: A2